AR074274A1 - Uso de tensioactivos cationicos para la inactivacion de toxinas - Google Patents
Uso de tensioactivos cationicos para la inactivacion de toxinasInfo
- Publication number
- AR074274A1 AR074274A1 ARP090104264A ARP090104264A AR074274A1 AR 074274 A1 AR074274 A1 AR 074274A1 AR P090104264 A ARP090104264 A AR P090104264A AR P090104264 A ARP090104264 A AR P090104264A AR 074274 A1 AR074274 A1 AR 074274A1
- Authority
- AR
- Argentina
- Prior art keywords
- lae
- use according
- inactivation
- ethyl
- acid
- Prior art date
Links
- 230000002779 inactivation Effects 0.000 title abstract 3
- 239000003053 toxin Substances 0.000 title abstract 2
- 231100000765 toxin Toxicity 0.000 title abstract 2
- 239000002158 endotoxin Substances 0.000 abstract 4
- 239000003093 cationic surfactant Substances 0.000 abstract 3
- 229930195730 Aflatoxin Natural products 0.000 abstract 2
- 239000005409 aflatoxin Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000002095 exotoxin Substances 0.000 abstract 2
- 231100000776 exotoxin Toxicity 0.000 abstract 2
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 2
- 238000007911 parenteral administration Methods 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 229960003589 arginine hydrochloride Drugs 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 238000009833 condensation Methods 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 150000002989 phenols Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000004671 saturated fatty acids Chemical class 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B2/00—Preservation of foods or foodstuffs, in general
- A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
- A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
- A23B2/729—Organic compounds; Microorganisms; Enzymes
- A23B2/742—Organic compounds containing oxygen
- A23B2/754—Organic compounds containing oxygen containing carboxyl groups
- A23B2/758—Carboxylic acid esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B2/00—Preservation of foods or foodstuffs, in general
- A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
- A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
- A23B2/729—Organic compounds; Microorganisms; Enzymes
- A23B2/762—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B2/00—Preservation of foods or foodstuffs, in general
- A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
- A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
- A23B2/729—Organic compounds; Microorganisms; Enzymes
- A23B2/771—Organic compounds containing hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere al uso de una composición para la inactivación de toxinas que contienen tensioactivos catiónicos tales como L-arginato de etil-Nalfa-lauroílo HCI (LAE). Se ha verificado que los tensioactivos catiónicos tales como el L-arginato de etil-Nalfa-lauroílo HCI (LAE) y sus sales son agentes eficaces contra endotoxinas, exotoxinas y aflatoxinas. Reivindicación 1: Uso de un tensioactivo catiónico derivado de la condensación de ácidos grasos y aminoácidos básicos esterificados de la fórmula (1), donde X- es un contra ión derivado de un ácido orgánico o inorgánico, preferiblemente Br-, Cl-, o HSO4-, o un anión sobre la base de un compuesto fenólico; R1 es una cadena alquílica recta de un ácido graso saturado o un ácido hidroxílico que tiene 8 a 14 átomos ligados al grupo aminoácido alfa a través de una ligadura amídica; R2 es una cadena alquílica recta o ramificada de 1 a 18 átomos de carbono o un grupo aromático; R3 es como en el grupo de fórmulas (2) en donde n es 0 a 4, para la inactivación de endotoxinas (lipopolisacáridos, LPS) desprendidos por bacterias Gram-negativas, exotoxinas o aflatoxinas. Reivindicación 3: Uso según la reivindicación 1 en un procedimiento para el tratamiento del cuerpo humano o animal por administración oral, tópica o parenteral. Reivindicación 8: Uso según la reivindicación 7, caracterizado porque la administración parenteral puede consistir en una forma líquida estéril. Reivindicación 12: Uso según cualquiera de las reivindicaciones 1 a 11, caracterizado porque el compuesto es el éster etílico de clorhidrato de arginina (LAE).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11670508P | 2008-11-21 | 2008-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074274A1 true AR074274A1 (es) | 2011-01-05 |
Family
ID=41718757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104264A AR074274A1 (es) | 2008-11-21 | 2009-11-04 | Uso de tensioactivos cationicos para la inactivacion de toxinas |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110230558A1 (es) |
| EP (1) | EP2346501B1 (es) |
| AR (1) | AR074274A1 (es) |
| ES (1) | ES2600253T3 (es) |
| WO (1) | WO2010057966A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010038952A1 (de) * | 2010-08-05 | 2012-02-09 | Henkel Ag & Co. Kgaa | Konservierungsmittel-Zusammensetzungen und Kosmetika enthaltend diese |
| KR20180064446A (ko) * | 2015-10-02 | 2018-06-14 | 에디컨인코포레이티드 | 의료 장치 및 유체를 처리하는 방법 및 시스템 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2455983C (en) * | 2001-08-09 | 2010-06-01 | Joan Baptista Urgell Beltran | Preservative systems and their use in cosmetic preparations |
| PT1437946E (pt) * | 2001-10-25 | 2012-07-25 | Miret Lab | Utilização de um conservante catiónico em produtos alimentares |
| CA2467244C (en) * | 2001-11-15 | 2011-01-04 | Laboratorios Miret S.A. | Use of cationic surfactant as antimicrobial activity enhancer in deodorants and oral care |
| US20070140990A1 (en) * | 2005-12-21 | 2007-06-21 | Nataly Fetissova | Oral Compositions Comprising Propolis |
| US20080200890A1 (en) * | 2006-12-11 | 2008-08-21 | 3M Innovative Properties Company | Antimicrobial disposable absorbent articles |
-
2009
- 2009-11-04 AR ARP090104264A patent/AR074274A1/es unknown
- 2009-11-20 US US13/129,817 patent/US20110230558A1/en not_active Abandoned
- 2009-11-20 WO PCT/EP2009/065524 patent/WO2010057966A1/en not_active Ceased
- 2009-11-20 ES ES09756735.8T patent/ES2600253T3/es active Active
- 2009-11-20 EP EP09756735.8A patent/EP2346501B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2600253T3 (es) | 2017-02-08 |
| WO2010057966A1 (en) | 2010-05-27 |
| US20110230558A1 (en) | 2011-09-22 |
| EP2346501A1 (en) | 2011-07-27 |
| EP2346501B1 (en) | 2016-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
| AR072462A1 (es) | Uso de surfactantes cationicos como agentes esporicidas | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| MX377255B (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| DOP2016000250A (es) | Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa | |
| BR112017009601A2 (pt) | derivados de aminoácidos e seus usos | |
| MX2019002632A (es) | Lipidos y composiciones novedosas para el suministro de agentes terapeuticos. | |
| BR112012013854A2 (pt) | derivados de oxazina. | |
| AR091089A1 (es) | Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada | |
| AR063923A1 (es) | Sales del acido zoledronico, procesos de preparacion y composiciones | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
| BR112014002670A2 (pt) | uso de monoésteres de isossorbida como compostos antimicrobianamente ativos | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
| AR086824A1 (es) | Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento | |
| PA8855001A1 (es) | Monocarbamas | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| CO6220906A2 (es) | Surfactantes de alquilamidopropil dialquilamina como adyuvantes | |
| CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
| AR084187A1 (es) | Composiciones para el cuidado oral | |
| CL2011001363A1 (es) | Proceso para la preparacion de un compuesto derivado de etorfina; compuesto derivado de etorfina; composicion farmaceutica que lo comprende; uso del compuesto como analgesico en el tratamiento del dolor. | |
| BR112014002570A2 (pt) | uso de monoésteres de isossorbida como espessantes | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |